Call Today: 800-716-5901
Contact us for free information or to start a free case review.
A new study suggests that women taking the osteoporosis drug Fosamax are twice as likely to develop a chronic heart condition known as atrial fibrillation.
The condition is marked by an irregular heartbeat and causes dizziness, fatigue and fainting.
The Research
Researchers at the University of Washington decided to examine the link between atrial fibrillation and Fosamax after a study linked a similar drug to an increased risk of abnormal heartbeat.
In the new study, researchers found that women who had taken Fosamax faced a higher risk of atrial fibrillation compared to women who did not take the drug. However, doctors say the results are inconclusive and more data is needed to confirm the risk.
Fosamax
Fosamax belongs to a class of drugs known as bisphosphonates. Drugs in this class have previously been linked to a serious jaw condition called ONJ, or osteonecrosis of the jaw.
(Source: USA Today)
Injured by Fosamax? Contact an attorney near you today to learn more about your legal options.
Copyright © 2001 - 2012 Online Lawyer Source
ATTORNEY ADVERTISEMENT—Thank you for your visit. The content published on this website was not written by medical professionals and should not, at any point, be mistaken for medical advice. Furthermore, the information on this site is intended for educational purposes only and should never interfere with a patient/site visitor and his or her healthcare provider. In addition, viewing the content on this website, requesting additional information, or transmitting information through a contact form should never be considered the formation of an attorney-client relationship. The material published on this site is general and may not apply to your specific circumstances. Every case comes with its own set of unique circumstances; past success discussed on this site does not guarantee future performance. Information found on this website should not be used as incentive to act without seeking counsel from a professional. For more information, please read our disclaimer.